Abstract:Background The primary objectives of the treatment for the lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) are to produce rapid, sustained, and safe improvements in the symptoms that affect the quality of life in the majority of men over 50. In this study, we evaluated the efficacy and safety of the combined therapy with terazosin (alpha 1-adrenergic receptor antagonist) and tolterodine (anticholinergic agent) for LUTS associated with BPH. Methods This combination study included 69 patients diagnosed with LUTS associated with BPH based on the International Prostate Symptom Scores (IPSS), urinary flow rate, prostate volume, urinary residual, and their serum prostate-specific antigen levels. Initially, 191 patients were treated with terazosin 2 mg once daily for one week. Those patients with continued LUTS after the initial treatment were allocated randomly into two groups: terazosin group (n=36) in which patients were treated with terazosin 2 mg once daily for six weeks, and combination group (n=33) in which patients were treated with both terazosin 2 mg once daily and tolterodine 2 mg twice daily for 6 weeks. Results The IPSS were significantly improved in both groups after treatment, and the reduction of IPSS in the combination group was significantly greater than that in the terazosin group (P < 0.01). A decrease in urgency, frequency and nocturia were the main contributory factors causing the reduction of IPSS in the combination group. The differences about the peak urinary flow rate and the residual urine from the baseline values were noted in both groups after treatment, but were not significant between the two groups. The incidence of adverse effects in the combination group was higher than that in the terazosin group. As expected the most common adverse effect was mouth dryness which was associated with anticholinergic drugs such as tolterodine. Conclusions Patients with LUTS associated BPH appear the improved IPSS after combined therapy with terazosin and tolterodine. This study, although short term and limited numbers of patients, provides evidence that the combined therapy with terazosin plus tolterodine is a good approach for meeting the objectives of rapid, sustained, and safe improvements in the LUTS associated with BPH. And the profile of patients in this study might be used as the indication of such combined therapy for LUTS associated with BPH without urodynamic evaluation.

Tamsulosin Combined with Solifenacin Versus Tamsulosin Monotherapy for Male Lower Urinary Tract Symptoms: a Meta-Analysis

Effects of Tamsulosin Combined with Solifenacin on Lower Urinary Tract Symptoms: Evidence from a Systematic Review, Meta-Analysis, and Trial Sequential Analysis of Randomized Controlled Trials.

Efficacy and Safety of Solifenacin Plus Tamsulosin Oral Controlled Absorption System in Men with Lower Urinary Tract Symptoms: a Meta-Analysis

A Systematic Review and Meta-Analysis of the Efficacy and Safety of Tamsulosin Plus Tadalafil Compared With Tamsulosin Alone in Treating Males With Lower Urinary Tract Symptoms Secondary to Benign Prostrate Hyperplasia

Combination of Tamsulosin and Tolterodine Alleviates Refractory Lower Urinary Tract Symptoms in Male Patients

Clinical Study of Combination Therapy of Tamsulosin and Solifenacin for Benign Prostatic Hyperplasia with Overactive Bladder

Combination of Solifenacin and Tamsulosin May Provide Additional Beneficial Effects for Ureteral Stent-Related Symptoms—outcomes from a Network Meta-Analysis

Combination Treatment of Solifenacin Plus Tamsulosin for Lower Urinary Tract Symptoms in Men with Parkinson's Disease

Application effects of solifenacin combined with tamsulosin in the mild and moderate benign prostatic hyperplasia with overactive bladder

The efficacy of vardenafil and tamsulosin in treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: A randomised clinical trial

Medical Expulsive Therapy for Ureteral Calculi with Tamsulosin: Evidence from A Meta-analysis of Randomized Controlled Trials

Efficacy and Safety of Combined Therapy with Terazosin and Tolteradine for Patients with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia: a Prospective Study

A Meta-Analysis of Efficacy and Safety of the New Α1a-Adrenoceptor-selective Antagonist Silodosin for Treating Lower Urinary Tract Symptoms Associated with BPH

The efficacy of combination therapy of tamsulosin and Qianlie Beixi capsule in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia

Defining the Efficacy and Safety of Phosphodiesterase Type 5 Inhibitors with Tamsulosin for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia with or without Erectile Dysfunction: A Network Meta-Analysis

Antimuscarinics and α-blockers or α-blockers monotherapy on lower urinary tract symptoms--a meta-analysis.

Addition of Antimuscarinics to Alpha-Blockers for Treatment of Lower Urinary Tract Symptoms in Men: a Meta-Analysis.

Efficacy And Safety Of Combinations Of Mirabegron And Solifenacin In Patients With Overactive Bladder: A Systematic Review And Meta-Analysis

Cognitive functions and health-related quality of life in men with benign prostatic hyperplasia and symptoms of overactive bladder when treated with a combination of tamsulosin and solifenacin in a higher dosage

To evaluate the efficacy and safety of different kinds of PDE5-Is with tamsulosin as a medical therapy for LUTS secondary to benign prostatic hyperplasia

Pooled-analysis of tadalafil and tamsulosin for ureteral calculi